NIFTP Thyroid Tumors: Ultrasound, Diagnosis, and Surgery

NIFTP, short for noninvasive follicular thyroid neoplasm with papillary-like nuclear features, is a thyroid tumor that used to be classified as cancer but was officially reclassified in 2016 as a non-malignant neoplasm. The change reflects decades of outcome data showing that these tumors behave in an extremely indolent way, with virtually no risk of recurrence or spread after surgical removal.¹ The reclassification has real consequences for patients: it means less aggressive surgery, no radioactive iodine treatment, and no lifelong “cancer survivor” label for tens of thousands of people diagnosed each year worldwide.

Why the Name Changed

Before 2016, these tumors were called encapsulated follicular variant of papillary thyroid carcinoma, or EFVPTC. That name carried the word “carcinoma,” and the diagnosis triggered a standard cancer treatment playbook: total thyroidectomy (removing the entire thyroid gland), followed by radioactive iodine ablation, then years of surveillance and thyroid hormone suppression therapy. The problem was that researchers kept observing the same thing in follow-up studies: patients with encapsulated, noninvasive EFVPTC almost never had recurrences, metastases, or cancer-related deaths. The tumor just sat there, walled off in its capsule, doing nothing.²

An international panel of thyroid pathologists examined the evidence and formally proposed the new name in a landmark 2016 paper. They developed a nuclear scoring system for diagnosing NIFTP that achieved roughly 94% overall classification accuracy.³ The intent was explicit: stop calling this cancer so that patients stop getting treated like cancer patients. The reclassification affects a meaningful number of people. A meta-analysis estimated that applying the NIFTP label worldwide would reclassify roughly 30,000 patients per year from “thyroid cancer” to “thyroid neoplasm,” though the impact varies by region, with a lower effect in Asia compared to North America and Europe.⁴

What a Pathologist Looks For

NIFTP cannot be diagnosed before surgery. The diagnosis requires the entire tumor in hand so a pathologist can examine its capsule, growth pattern, and nuclear features under the microscope. The tumor is an encapsulated or clearly bordered growth with a follicular architecture, meaning cells arranged in small round structures, and nuclei that look like those seen in papillary thyroid carcinoma.⁵ Those papillary-like nuclear features are the reason NIFTP was previously lumped in with papillary thyroid cancer in the first place: under the microscope, the cell nuclei share certain optical characteristics (clearing, grooves, overlapping) that define the papillary cancer family.

The 2022 WHO classification lays out a checklist of features that must all be present for a NIFTP diagnosis:

Encapsulation or clear demarcation: the tumor must be fully contained within a capsule or have a well-defined border.
Follicular growth pattern: less than 1% true papillae (the finger-like projections typical of classic papillary carcinoma).
No psammoma bodies: those characteristic calcified concentric rings found in classic papillary cancer are absent.
Limited solid growth: less than 30% solid, trabecular, or insular pattern.
Nuclear score of 2 or 3: on a three-point scale measuring papillary-type nuclear changes.
No invasion: no capsular penetration, no vascular invasion.
No necrosis and low mitotic activity: fewer than 3 mitoses per 2 mm².

If any one of these criteria is not met, the tumor cannot be called NIFTP and may instead be classified as a true carcinoma requiring more aggressive treatment.⁶

Why It Cannot Be Diagnosed Before Surgery

One of the frustrating realities of NIFTP is that a needle biopsy (fine needle aspiration, or FNA) taken before surgery cannot reliably tell you whether a nodule is NIFTP. The reason is straightforward: the diagnosis hinges on evaluating the entire capsule for invasion, which no needle sample can do. On cytology, NIFTP cells look a lot like cells from other follicular-patterned tumors and even from some papillary cancers. A systematic review of over 900 NIFTP cases found that about 30% were categorized as “atypia of undetermined significance,” 21% as “suspicious for follicular neoplasm,” 24% as “suspicious for malignancy,” and only about 10% were called benign on the initial biopsy.⁷ In other words, most NIFTPs fall into the indeterminate gray zone on biopsy, which is exactly the category where the hardest surgical decisions live.

Because of this overlap, NIFTP’s existence has forced a recalculation of what indeterminate biopsy results actually mean. Before reclassification, all those NIFTPs counted as “malignant” in the final surgical outcome data, inflating the apparent cancer risk of indeterminate biopsies. Now that NIFTPs are no longer considered malignant, the true cancer risk for an indeterminate biopsy is lower than previously thought.⁸ This adjustment also affects the performance of molecular tests used to triage indeterminate nodules. Tools like Afirma GEC and ThyroSeq v2, which were calibrated to earlier malignancy rates, have had their diagnostic accuracy affected by the NIFTP reclassification, and newer versions of these tests have had to account for it.⁹

What NIFTP Looks Like on Ultrasound

On ultrasound, NIFTP tends to look bland and reassuring. Most NIFTPs appear as solid, mildly hypoechoic (slightly darker than surrounding tissue) nodules with smooth margins, a wider-than-tall shape, no suspicious calcifications, and blood flow around rather than through the nodule.¹⁰ Under risk stratification systems like TIRADS, roughly three-quarters of NIFTPs are classified as low risk.¹¹

The catch is that NIFTP looks essentially identical on ultrasound to follicular adenoma (a benign tumor) and follicular thyroid carcinoma (a true cancer). Researchers comparing ultrasound features across these tumor types found that NIFTP and follicular adenoma were statistically indistinguishable on imaging, while classic papillary carcinoma had clearly different features like irregular margins and calcifications.¹² So while ultrasound can usually separate NIFTP from classic papillary cancer, it cannot reliably distinguish NIFTP from other follicular lesions. This overlap is another reason the final diagnosis waits until surgery.

The Molecular Fingerprint

Genetically, NIFTP is distinct from classic papillary thyroid carcinoma in a way that reinforces the reclassification. Classic papillary cancers are frequently driven by a specific mutation called BRAF V600E, while NIFTP is predominantly driven by RAS-family mutations. A study testing 92 confirmed NIFTPs found that none carried the BRAF V600E mutation.¹³ This molecular profile aligns NIFTP more closely with follicular adenomas and low-risk follicular carcinomas than with the papillary cancers it used to be grouped with.

This distinction has practical diagnostic value. If a molecular test on a preoperative biopsy comes back positive for BRAF V600E, the nodule is very unlikely to be NIFTP. It is almost certainly a true papillary carcinoma and should be treated accordingly. On the other hand, finding a RAS mutation does not confirm NIFTP, since RAS mutations also appear in follicular adenomas and some true carcinomas. Still, it nudges the probability toward a less aggressive tumor.

Treatment After Diagnosis

The whole point of the reclassification was to de-escalate treatment. Because NIFTP is no longer classified as cancer, the recommended approach is lobectomy, removing only the half of the thyroid that contains the tumor, rather than a total thyroidectomy.¹⁴ This preserves thyroid function in many patients and reduces the risk of surgical complications like damage to the parathyroid glands or recurrent laryngeal nerve.

Equally significant is what NIFTP patients do not need: radioactive iodine therapy. Under the old classification, many of these patients received radioactive iodine after surgery. In one cohort study, just over half of NIFTP patients had received it before reclassification guidelines caught up.¹⁵ Radioactive iodine is not a trivial intervention: it requires isolation from family members, carries a small increased risk of secondary cancers, and can cause salivary gland damage and other side effects. Eliminating it for NIFTP patients removes a meaningful burden. Research on tumors 4 cm and larger, treated without radioactive iodine, found favorable long-term outcomes, suggesting even larger NIFTPs do not require this treatment.¹⁶

Long-Term Outcomes

The prognosis for NIFTP is about as good as it gets for a surgical diagnosis. Studies with follow-up periods stretching over a decade consistently show zero or near-zero recurrence rates after complete excision. A French registry study found no recurrences in its entire NIFTP cohort, including patients with tumors 4 cm or larger and those who did not receive radioactive iodine.¹⁷ A U.S. population-based study estimated that NIFTP accounts for roughly 17% of all well-differentiated thyroid cancers after recategorization.¹⁸ That is a substantial chunk of what was previously counted as thyroid cancer being reclassified as something that behaves more like a benign condition.

The Cost Savings Are Substantial

De-escalated treatment for NIFTP is not only better for patients, it is considerably cheaper. A cost-effectiveness analysis modeled the financial impact over a five-year period and found that managing a tumor as NIFTP (lobectomy alone, no radioactive iodine, less intensive surveillance) cost about $12,400 per patient, compared to roughly $16,300 per patient under the old cancer-treatment approach. That is nearly $3,900 saved per patient. Scaled across the U.S. population of affected patients, the analysis estimated total savings of $6 to $42 million over five years, with a gain of 54 to 370 quality-adjusted life years. The de-escalated approach was not only cheaper, it also produced slightly better quality-of-life outcomes, mainly because patients avoided unnecessary completion surgeries and radioactive iodine treatments.¹⁹

The Diagnostic Gray Zone in the Operating Room

Surgeons sometimes request a frozen section during an operation, hoping the pathologist can provide an immediate diagnosis and guide whether to remove the remaining thyroid lobe or stop after a lobectomy. For follicular-patterned lesions like NIFTP, this approach has serious limitations. A meta-analysis found that frozen section had an overall sensitivity of only about 43% for follicular neoplasms, meaning it misses the majority of malignancies.²⁰ The reason is the same one that makes preoperative biopsy unreliable for NIFTP: determining invasion requires careful, complete examination of the tumor capsule, which can only be done properly on permanent sections prepared after the operation, not on hastily frozen tissue slices.²¹ Worse, the freezing process can distort the capsule and make later permanent-section evaluation harder, potentially jeopardizing the final diagnosis.²²

For NIFTP specifically, this means the diagnosis almost always comes days after surgery when the permanent sections are ready. The practical implication is that many patients learn only after their operation whether they had a cancer or a NIFTP. When a lobectomy was performed and the final diagnosis is NIFTP, no further surgery is needed. This is one of the reasons that lobectomy, rather than total thyroidectomy, is now favored for indeterminate nodules suspected of being follicular neoplasms: it gives the pathologist enough tissue to make the diagnosis without committing the patient to losing their entire gland upfront.

Pathologist Agreement Is Not Perfect

One ongoing challenge with NIFTP is that pathologists do not always agree on the diagnosis. The nuclear features that distinguish NIFTP from a benign follicular adenoma on one hand, and from a true papillary carcinoma on the other, can be subtle and subjective. A study of interobserver agreement among pathologists evaluating NIFTP nuclear criteria found only moderate overall agreement, with some individual features like nuclear enlargement showing only slight agreement between reviewers.²³ This variability is one reason NIFTP incidence varies significantly by geographic region. In parts of Asia, where pathologists have historically applied stricter criteria for papillary-type nuclear features, fewer tumors get classified as NIFTP in the first place.

NIFTP in Younger Patients

Most of the literature on NIFTP comes from adult populations, so a natural question is whether the same reassuring profile applies to adolescents and young adults. The answer appears to be yes, with an important caveat: NIFTP is rare in young children and mainly shows up in adolescents and young adults. A study from a pediatric center identified 10 NIFTP cases in patients aged 15 to 26, all of which had RAS or RAS-like molecular alterations and none of which recurred over a follow-up period ranging from 13 to 86 months.²⁴ Another study of pediatric thyroid FNA cases found that NIFTP made up a very small fraction of surgical outcomes, just under 2% of cases.²⁵ A separate institutional review confirmed the pattern: the few pediatric NIFTP cases identified were all unifocal, low stage, free of lymph node involvement, and showed no recurrence over follow-up periods as long as eleven years.²⁶ Conservative treatment along adult NIFTP guidelines appears reasonable for this age group, though the numbers are small and longer-term data would be welcome.

The Emotional Side of Being “Un-Diagnosed”

One dimension that gets little attention in the medical literature is how patients feel when told that what they were treated for as cancer is no longer considered cancer. You might assume the reaction would be relief, but a qualitative study exploring this found something more complicated. Overwhelmingly, participants expressed anxiety rather than comfort. Many felt distress about having undergone surgeries and radioactive iodine treatment that might have been unnecessary. One participant worried about long-term calcium problems from surgery; another expressed frustration about the uncertainty of what might change next in medical definitions. Patients who had received radioactive iodine were especially troubled, knowing it carries a small increased risk of other cancers.²⁷

This finding has practical implications for how doctors communicate the reclassification. Simply mailing a letter saying “your cancer is no longer considered cancer” is not enough and may do more harm than good. Patients benefit from a conversation that explains why the name changed, reassures them that the original treatment was appropriate given what was known at the time, and acknowledges the emotional weight of having their medical history rewritten. Clinicians who treat thyroid conditions are still working out the best way to deliver this kind of news.

Active Surveillance as an Alternative to Immediate Surgery

An emerging question is whether some patients with nodules that are likely to turn out to be NIFTP even need surgery at all, or whether monitoring with periodic ultrasound could be a safe option. Because NIFTP cannot be definitively diagnosed without removing the tumor, active surveillance in this context means watching nodules that fall into the indeterminate biopsy categories where NIFTP is common. A recent real-world study of active surveillance for Bethesda category IV nodules (suspicious for follicular neoplasm) found high stability, low rates of malignancy, and low rates of eventual surgery, supporting its feasibility in selected patients.²⁸ This approach is still being studied and is far from standard practice, but it reflects the broader trend toward less aggressive management of thyroid nodules that are unlikely to cause harm. For patients who are poor surgical candidates or who strongly prefer to avoid an operation, surveillance guided by ultrasound and clinical features may be a reasonable conversation to have with an endocrinologist.